Literature DB >> 9333075

Pyronaridine for treatment of Plasmodium ovale and Plasmodium malariae infections.

P Ringwald1, J Bickii, A Same-Ekobo, L K Basco.   

Abstract

The clinical efficacy of oral pyronaridine was assessed in 22 symptomatic Cameroonian patients infected with Plasmodium ovale or Plasmodium malariae. All patients were cured on or before day 4. In vitro drug assays confirmed the sensitivity of P. ovale and P. malariae isolates to chloroquine and pyronaridine.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9333075      PMCID： PMC164120     

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  In vitro activity of antimalarials against clinical isolates of Plasmodium falciparum in Yaounde, Cameroon.

Authors:  P Ringwald; J Bickii; L K Basco
Journal:  Am J Trop Med Hyg       Date:  1996-09       Impact factor: 2.345

Review 2.  Status of antimalarial drugs under development.

Authors:  P L Olliaro; P I Trigg
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

3.  Clinical study of pyronaridine for the treatment of acute uncomplicated falciparum malaria in Thailand.

Authors:  S Looareesuwan; D E Kyle; C Viravan; S Vanijanonta; P Wilairatana; W H Wernsdorfer
Journal:  Am J Trop Med Hyg       Date:  1996-02       Impact factor: 2.345

4.  First report of in vitro susceptibility of Plasmodium malariae Thai isolates to chloroquine.

Authors:  P Tan-ariya; S Pasuralertsakul
Journal:  Southeast Asian J Trop Med Public Health       Date:  1994-12       Impact factor: 0.267

5.  Short-term in vitro culture of Plasmodium vivax and P. ovale for drug-susceptibility testing.

Authors:  L K Basco; J Le Bras
Journal:  Parasitol Res       Date:  1994       Impact factor: 2.289

Review 6.  Studies on a new antimalarial compound: pyronaridine.

Authors:  C Chang; T Lin-Hua; C Jantanavivat
Journal:  Trans R Soc Trop Med Hyg       Date:  1992 Jan-Feb       Impact factor: 2.184

7.  Treatment of chloroquine-resistant Plasmodium vivax with chloroquine and primaquine or halofantrine.

Authors:  J K Baird; H Basri; B Subianto; D J Fryauff; P D McElroy; B Leksana; T L Richie; S Masbar; F S Wignall; S L Hoffman
Journal:  J Infect Dis       Date:  1995-06       Impact factor: 5.226

8.  Pyronaridine: A new antimalarial drug.

Authors:  S Fu; S H Xiao
Journal:  Parasitol Today       Date:  1991-11

9.  Adaptations of the Saker-Solomons test: simple, reliable colorimetric field assays for chloroquine and its metabolites in urine.

Authors:  D L Mount; B L Nahlen; L C Patchen; F C Churchill
Journal:  Bull World Health Organ       Date:  1989       Impact factor: 9.408

10.  Randomised trial of pyronaridine versus chloroquine for acute uncomplicated falciparum malaria in Africa.

Authors:  P Ringwald; J Bickii; L Basco
Journal:  Lancet       Date:  1996-01-06       Impact factor: 79.321
  10 in total
  7 in total

1.  In vivo and in vitro efficacy of chloroquine against Plasmodium malariae and P. ovale in Papua, Indonesia.

Authors:  H Siswantoro; B Russell; A Ratcliff; B Prasetyorini; F Chalfein; J Marfurt; E Kenangalem; M Wuwung; K A Piera; E P Ebsworth; N M Anstey; E Tjitra; R N Price
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

2.  Review of pyronaridine anti-malarial properties and product characteristics.

Authors:  Simon L Croft; Stephan Duparc; Sarah J Arbe-Barnes; J Carl Craft; Chang-Sik Shin; Lawrence Fleckenstein; Isabelle Borghini-Fuhrer; Han-Jong Rim
Journal:  Malar J       Date:  2012-08-09       Impact factor: 2.979

3.  Global gene expression profiling of Plasmodium falciparum in response to the anti-malarial drug pyronaridine.

Authors:  Kanyanan Kritsiriwuthinan; Sastra Chaotheing; Philip J Shaw; Chayaphat Wongsombat; Porntip Chavalitshewinkoon-Petmitr; Sumalee Kamchonwongpaisan
Journal:  Malar J       Date:  2011-08-18       Impact factor: 2.979

4.  Development of antimalarial drugs and their application in China: a historical review.

Authors:  Chang Chen
Journal:  Infect Dis Poverty       Date:  2014-03-20       Impact factor: 4.520

Review 5.  A systematic review of the clinical presentation, treatment and relapse characteristics of human Plasmodium ovale malaria.

Authors:  Mirjam Groger; Hannah S Fischer; Luzia Veletzky; Albert Lalremruata; Michael Ramharter
Journal:  Malar J       Date:  2017-03-11       Impact factor: 2.979

6.  Methnaridine is an orally bioavailable, fast-killing and long-acting antimalarial agent that cures Plasmodium infections in mice.

Authors:  Weisi Wang; Junmin Yao; Zhuo Chen; Yiming Sun; Yuqing Shi; Yufen Wei; Hejun Zhou; Yingfang Yu; Shizhu Li; Liping Duan
Journal:  Br J Pharmacol       Date:  2020-10-30       Impact factor: 8.739

7.  Genetic analysis of the orthologous crt and mdr1 genes in Plasmodium malariae from Thailand and Myanmar.

Authors:  Yupawadee Pimpat; Naowarat Saralamba; Usa Boonyuen; Sasithon Pukrittayakamee; Francois Nosten; Frank Smithuis; Nicholas P J Day; Arjen M Dondorp; Mallika Imwong
Journal:  Malar J       Date:  2020-08-31       Impact factor: 2.979
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.